Monument Naming and Identification Ability in Aging and Alzheimer’s
Official title: The Monument Test : A New Tool for Assessing the Ability to Name and Identify Unique Entities. (TeDIMO)
Run by University Hospital, Grenoble · NCT07367880 · Data updated 2026-11-12
This study tests whether healthy older adults and people with Alzheimer’s disease differ in naming and identifying famous monuments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 50 Years to 95 Years |
| Sex | All |
| Enrollment | 220 (estimated) |
| Sponsor | University Hospital, Grenoble Academic / other |
| Locations | 1 site (Grenoble) |
| Status | Recruiting |
| Started | February 23, 2026 |
| Main results expected | February 1, 2031 |
| Study ends | February 1, 2032 |
| Registry record updated | May 26, 2026 |
| Trial ID | NCT07367880 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 50 or older with probable/possible Alzheimer’s disease (MMSE 18–26) and cognitively healthy controls (MMSE ≥26).
✕Probably not a fit
Individuals with significant language or sensory impairments, or those unable to comprehend French, may not benefit from or complete the task.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study compares performance on an identification and naming task involving famous monuments between two groups: healthy elderly participants and individuals with Alzheimer’s disease. Participants are 50 years or older and grouped by MMSE scores (Alzheimer’s: 18–26; controls: 26 or higher). The task measures how accurately and quickly participants can denominate and recognize landmark images or names. The study aims to show a significant performance difference between the groups. No intervention is performed beyond the identification task.
Why it matters
Potential benefit: If successful, the task could help refine cognitive profiling and aid in developing diagnostics related to semantic memory and landmark recognition.
How similar studies have gone: Previous work has explored naming and recognition in aging and dementia populations, with some studies showing distinct deficits in semantic and landmark recognition.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria : * Alzheimer's disease: * Age ≥ 50 years and older * Possible or probable diagnosis of Alzheimer's disease according to the revised criteria of Mac Khann et al., 2011. * Score 18≤ MMSE ≤26 * Controls: * Age ≥ 50 years and older * MMSE score ≥ 26 For all subjects * No objection from the participant Exclusion criteria * Alzheimer's disease: * Persons referred to in Articles L1121-5 to L1121-8 of the CSP * Controls: * Memory complaints * Persons referred to in Articles L1121-5 to L1121-8 of the CSP For all subjects * Significant neurological or psychiatric history * Taking psychotropic medication (neuroleptics) * Poor command of the French language, comprehension difficulties * Significant hearing or visual impairments (diplopia, nystagmus, scotoma, etc.) * Insufficient exposure to the media and/or socio-cultural knowledge (questionnaire) ; Deficit in face recognition (Benton Face Recognition Test)
Where it's running
-
CHU Grenoble Alpes
Grenoble, France Recruiting
Study contacts
- Study coordinator: Sabrina Iannuzzi, Neuropsychologist
- Email: siannuzzi@chu-grenoble.fr
- Phone: +334.76.76.57.90
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Acoustic Stimulation During Sleep for Alzheimer’s Disease
Researchers test whether playing gentle sounds during sleep can help people with Alzheimer’s disease see if their thinking improves compared with a sham sound.
-
FAME: A Italian test to recognize famous faces and name them
This project tests an Italian battery to see how well people with stroke or neurodegenerative diseases recognize famous faces and recall their names, familiarity, and related facts.
-
NMS-01 safety test in people with mild to moderate Alzheimer's disease
This pilot test checks whether the focused ultrasound device NMS-01 is safe and can briefly open the blood-brain barrier in adults with mild-to-moderate Alzheimer's disease.
-
Choose Myself (Before) Losing Myself
We’re testing an educational interactive booklet to help people with dementia or memory problems think about future medical decisions and start conversations with family or caregivers.
-
Lecanemab-irmb in Real-World Use for Alzheimer’s Disease
This study tests the safety of lecanemab-irmb in people with Alzheimer’s disease by looking at real-world brain-image changes and related events.
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.